MedDataX Logo

Amino Acid and Intestinal Protein Metabolism : Working Study

NCT ID: NCT01254110

Last Updated: 2013-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-04-30

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gut protein metabolism that could be influenced by protein supply is involved in the regulation of several physiological functions such as gut barrier function and represents a major contribution in the whole-body protein turnover. Intracellular pathways implicated in the transduction of amino acids effects remained unknown in the human gut. Thus, the aim of the present project is to evaluate and to understand the effects of amino acids (glutamine, leucine) on gut protein metabolism (synthesis and degradation) in young healthy humans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transduction Pathway Proteinic Synthesis Proteolytic System

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Enterally fed with leucine

No interventions assigned to this group

2

Enterally fed with glutamine

No interventions assigned to this group

3

Enterally fed with protein powder

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* volunteers with seronegativity for HIV1 and HIV2 and HCV and HVB
* good nutritional state with physical indication mass included between 18,5 and 25kg/m2
* non-smoking volunteers
* volunteers without digestive, allergic or haemorrhagic history
* volunteers without progressive disease
* digestive endoscopy tolerance
* age \>=18 and \<= 50years
* consent obtained from volunteers

Exclusion Criteria

* smoking volunteers
* volunteers with digestive, or allergic history
* volunteers with haemorrhagic sign
* pregnancy
* progressive digestive disease
* significant progressive disease
* volunteers with therapeutic treatment (aspirin)
* digestive endoscopy intolerance
* volunteers with neurological disorder or with delicate psychological state
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Rouen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Moise COEFFIER

Role: STUDY_CHAIR

UH Rouen

Anne-Françoise CAILLEUX, Doctor

Role: STUDY_CHAIR

UH Rouen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre d'Investigation Clinique - Hôpital charles Nicolle

Rouen, Seine maritime, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Goichon A, Bertrand J, Chan P, Lecleire S, Coquard A, Cailleux AF, Vaudry D, Dechelotte P, Coeffier M. Enteral delivery of proteins enhances the expression of proteins involved in the cytoskeleton and protein biosynthesis in human duodenal mucosa. Am J Clin Nutr. 2015 Aug;102(2):359-67. doi: 10.3945/ajcn.114.104216. Epub 2015 Jun 24.

Reference Type DERIVED
PMID: 26109581 (View on PubMed)

Bertrand J, Goichon A, Chan P, Azhar S, Lecleire S, Donnadieu N, Vaudry D, Cailleux AF, Dechelotte P, Coeffier M. Enteral glutamine infusion modulates ubiquitination of heat shock proteins, Grp-75 and Apg-2, in the human duodenal mucosa. Amino Acids. 2014 Apr;46(4):1059-67. doi: 10.1007/s00726-014-1670-x. Epub 2014 Jan 22.

Reference Type DERIVED
PMID: 24449167 (View on PubMed)

Coeffier M, Claeyssens S, Bole-Feysot C, Guerin C, Maurer B, Lecleire S, Lavoinne A, Donnadieu N, Cailleux AF, Dechelotte P. Enteral delivery of proteins stimulates protein synthesis in human duodenal mucosa in the fed state through a mammalian target of rapamycin-independent pathway. Am J Clin Nutr. 2013 Feb;97(2):286-94. doi: 10.3945/ajcn.112.046946. Epub 2013 Jan 2.

Reference Type DERIVED
PMID: 23283505 (View on PubMed)

Coeffier M, Claeyssens S, Bensifi M, Lecleire S, Boukhettala N, Maurer B, Donnadieu N, Lavoinne A, Cailleux AF, Dechelotte P. Influence of leucine on protein metabolism, phosphokinase expression, and cell proliferation in human duodenum1,3. Am J Clin Nutr. 2011 Jun;93(6):1255-62. doi: 10.3945/ajcn.111.013649. Epub 2011 Apr 20.

Reference Type DERIVED
PMID: 21508089 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ID RCB 2008-A00692-53

Identifier Type: -

Identifier Source: secondary_id

2007/142/HP

Identifier Type: -

Identifier Source: org_study_id